---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013191"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:22:31.630767+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Collegium Q2 net revenue $135.5M (+10% YoY); GAAP net income $13.0M vs loss; authorizes $50M buyback

## Summary
- Q2 GAAP net income $13.0M ($0.34 diluted EPS) vs GAAP net loss of $5.2M a year ago; adjusted EBITDA $85.8M, up 21% YoY.
- Board authorized $50M accelerated share repurchase program; reaffirmed FY2023 guidance product revenue $565-580M, adjusted EBITDA $355-370M.
- Xtampza ER revenue grew 24% YoY to $41.2M; Nucynta franchise revenue up 8% YoY to $47.3M; Belbuca prescriptions up 3.5% QoQ.
- FDA approved Nucynta for children ages 6+; pediatric extension could extend exclusivity to Dec 2025.

## SEC filing metadata
- accession: 0001558370-23-013191
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/0001558370-23-013191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/coll-20230803x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013191
- JSON: https://secwatch.observer/filing/0001558370-23-013191.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013191.txt

## Key facts
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported quarter ended June 30, 2023 results: revenue $135.5 million, net income $13.0 million, EPS $0.34 GAAP earnings per share (diluted). Guidance reaffirmed.
  - Period: quarter ended June 30, 2023
  - Revenue: $135.5 million
  - Net income: $13.0 million
  - EPS: $0.34 GAAP earnings per share (diluted)
  - Guidance: reaffirmed
  - Result: reported results
  source text: of this Current Report on Form 8-K. ​ --- EX-99.1 (EX-99.1) --- ​ Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year ​ – Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – ​ – Q2’23 GAAP Net Income of $13.0 Million – ​ – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – ​ – Board of Directors has Authorized
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000155837023013191/0001558370-23-013191-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.